Hisun Pharm Hangzhou Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HISUN PHARM HANGZHOU, and what generic and branded alternatives to HISUN PHARM HANGZHOU drugs are available?
HISUN PHARM HANGZHOU has twenty approved drugs.
Drugs and US Patents for Hisun Pharm Hangzhou
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hisun Pharm Hangzhou | DAPTOMYCIN | daptomycin | POWDER;INTRAVENOUS | 212250-001 | Apr 21, 2021 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Hisun Pharm Hangzhou | TELMISARTAN | telmisartan | TABLET;ORAL | 207843-001 | Feb 19, 2019 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Hisun Pharm Hangzhou | OLANZAPINE | olanzapine | TABLET;ORAL | 206924-002 | Dec 31, 2020 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.